Informations générales (source: ClinicalTrials.gov)
A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies
Interventional
Phase 1/Phase 2
AstraZeneca (Voir sur ClinicalTrials)
janvier 2025
mai 2030
16 novembre 2026
The purpose of this study is to assess the safety and efficacy of surovatamig (formerly
AZD0486) administered as monotherapy or in combination with other anticancer agents in
participants with hematological malignancies
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Vincent RIBRAG | 15/11/2026 21:25:02 | Contacter | ||
Critères
Tous
Master Inclusion Criteria applicable to all substudies:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Contraception use during treatment and at least 90 days after final dose.
- Confirmed CD19 expression if prior anti-CD19 therapy.
Substudy 1 Specific Inclusion Criteria:
- Participants with CLL must require treatment according to the international workshop
on Chronic Lymphocytic Leukemia (iwCLL) criteria.
- SLL: at least 1 measurable site per Lugano.
- Absolute lymphocyte count (ALC) <25000 cells/mcL.
- Cohort 1A and 1C: at least 2 prior lines of systemic therapy for CLL/SLL.
- Cohort 1B: at least 1 prior line of therapy and is bruton tyrosine kinase inhibitor
(BTKi)-sensitive.
Substudy 2 Specific Inclusion Criteria:
- MCL diagnosis per WHO.
- Clinical Stage II, III, or IV by Ann Arbor Classification.
- At least 1 measurable site per Lugano.
- ALC < 25000 cells/mcL.
- Cohort 2A and 2C: Relapse or progressed after 2 or more lines of therapy including
BTKi.
Substudy 3 Specific Inclusion Criteria:
- At least 1 measurable site as per Lugano.
- Left ventricular ejection fraction (LVEF) ≥50%.
- Participant must be no older than 79 years of age at the time of signing ICF.
- Contraception at least 90 days after last dose of surovatamig or 4 months after last
dose of vincristine, and 6 months after the last dose of cyclophosphamide, or
doxorubicin.
- Cohort 3A:
1. Histologically confirmed diagnosis of previously untreated large B-cell
Lymphoma (LBCL) per WHO 2022.
2. R/R B-NHL after at least 1 prior lines of systemic therapy.
3. International Prognostic Index (IPI) 2-5.
- Cohort 3B:
1. Histologically confirmed diagnosis of previously untreated large B-cell
Lymphoma (LBCL) per WHO 2022.
2. IPI score of 2 to 5.
Exclusion Criteria:
Master Exclusion Criteria applicable to all substudies:
- Central nervous system (CNS) lymphoma.
- Surgery within 14 days of study drug.
- Clinically significant cardiovascular (CV) disease.
- Unresolved Grade >2 AEs from prior anticancer therapy (except alopecia or fatigue).
- Any systemic therapy within 5 half-lives or 21 days (whichever is shorter) prior to
treatment.
- Radiation therapy within 28 days.
- Prior CAR T-cell therapy or autologous-haematopoietic stem cell transplant (HSCT)
within 12 weeks or prior T-cell engager (TCE) within 8 weeks.
- Prior Grade > 3 cytokine release syndrome (CRS) or immune effector cell-associated
neurotoxicity syndrome (ICANS) event.
- Prior allogeneic HSCT or solid organ transplantation within 24 weeks of starting
Cycle 1 Day 1.
- Active, significant, uncontrolled infection or autoimmune disease requiring systemic
therapy including participants with known history of haemophagocytic
lymphohistiocytosis (HLH).
Substudy 1 Specific Exclusion Criteria:
- CLL/SLL transformation to more aggressive form of lymphoma.
- Cohort 1B: bleeding diathesis, CYP3A inhibitor or inducer, history of ICH or stroke
within 24 weeks, GI malabsorption, receiving vitamin K antagonist.
Substudy 3 Specific Exclusion Criteria:
- Mediastinal grey-zone lymphoma, Burkitt, Richter's transformation, primary effusion
large B-cell lymphoma (LBCL).
- Cumulative dose of anthracycline >150 mg/m2.